• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Blog
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    Medical
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training
Pharmintel

Unmet Medical Need Analysis of vaso-occlusive crisis in sickle cell disease: Approval of Adakveo (crizanlizumab-tmca)

On May 15, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older.

Unmet Medical Need ParametersCurrent Unmet Medical Need in vaso-occlusive crisis in sickle cell diseaseUnmet Medical Need after Adakveo (crizanlizumab-tmca)
Low to moderate unmet medical needLow to moderate unmet medical need
Disease SeverityVaso-occlusive crisis and chronic pain are associated with considerable economic loss and disabilityVaso-occlusive crisis and chronic pain are associated with considerable economic loss and disability
Treatment Adequacy Current treatment (Endari) affects episodes frequencyNew treatment also affects episodes frequency
Concerns of Payers & Providers• Median number of sickle cell crises
• Median number of hospitalizations for sickle cell pain
• Median cumulative days in hospital
• Median time (days) to first sickle cell crisis
• Patients with occurrences of acute chest syndrome
• Annual rate of VOC (vaso-occlusive crises)
• Annual rate of days hospitalized
Net Unmet Medical Need Score2.46/52.34/5

Adakveo has disease modifying effect, affects disease severity and provides symptomatic relief as well as addresses patients, payers and providers concerns.

To get detailed analysis of unmet medical need and to understand our approach which we are using for unmet medical analysis of any disease please contact at [email protected]

We help researchers in unmet medical need analysis of diseases which helps them in disease prioritization for any new drug/device/target/MOA development. We do unmet medical need analysis of any disease based on various parameters which is not limited to treatment adequacy, patient perspective, payer & providers perspective.

Leave a Reply

Your email address will not be published.

Contact
+91 9643310025, 9643312749
© 2019 Pharmintel